News | August 04, 2009

MDS Nordion Says MAPLE Reactors Could Solve the Isotope Crisis


August 4, 2009 - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has submitted a proposal to Canada’s Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) Generator Production, stating the best answer to the shortage of medical radioisotopes is the completion and bringing into service of the MAPLE project.

With no domestic or international sources of supply that can fully mitigate the current global shortage of medical isotopes, MDS Nordion urges Atomic Energy of Canada Limited (AECL) to complete the MAPLE project to address this shortage. With expertise and guidance from the South African Nuclear Energy Corp. (Necsa), owner and operator of the SAFARI-1 reactor, and working with AECL, MDS Nordion believes a solution could be achieved in an estimated 24 months.

MDS Nordion urges AECL to honor its long-standing commitment to replace the National Research Universal (NRU) by bringing the MAPLE facilities into service. This company says it can be done through AECL collaborating with Necsa on the adaption of the OSCAR computer codes, which are successfully used by the world’s leading isotope producing reactors. The computer codes are specifically designed to model research reactor performance and operation and are being used by the High Flux Reactor in Petten, Netherlands, and SAFARI-1, in South Africa. MDS Nordion says adopting the OSCAR computer codes could be essential to resolving the existing discrepancy between the predicted and measured value of the power coefficient of reactivity of the MAPLE reactors allowing them to be licensed by the Canadian Nuclear Safety Commission (CNSC) for safe operation.

In addition to the OSCAR computer codes, MDS Nordion is proposing the construction of a fully licensed production facility to manufacture Tc-99m generators for distribution to Canadian hospitals in all regions of Canada and abroad. MDS Nordion said it will build, operate and maintain the generator production line, and perform all necessary activities; including provision of licensed packaging, consumable supplies and facilitate transport logistics to all Canadian healthcare centers.

For more information: www.mdsnordion.com


Related Content

News | Radiopharmaceuticals and Tracers

April 13, 2023 — A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin ...

Home April 13, 2023
Home
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Home November 05, 2022
Home
News | Radiopharmaceuticals and Tracers

June 24, 2022 — Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive ...

Home June 24, 2022
Home
News | Radiopharmaceuticals and Tracers

August 2, 2019 — The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) ...

Home August 02, 2019
Home
News | Radiopharmaceuticals and Tracers

July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot ...

Home July 16, 2019
Home
News | Radiopharmaceuticals and Tracers

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel ...

Home June 05, 2019
Home
News | Radiopharmaceuticals and Tracers

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular ...

Home May 17, 2019
Home
News | Radiopharmaceuticals and Tracers | Jeff Zagoudis, Associate Editor

May 10, 2019 — Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in ...

Home May 10, 2019
Home
News | Radiopharmaceuticals and Tracers

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide ...

Home October 12, 2018
Home
Feature | Radiopharmaceuticals and Tracers | Dave Fornell

February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took ...

Home February 26, 2018
Home
Subscribe Now